Annual Cash & Cash Equivalents:
$344.07M-$15.22M(-4.24%)Summary
- As of today, TXG annual cash & cash equivalents is $344.07 million, with the most recent change of -$15.22 million (-4.24%) on December 31, 2024.
- During the last 3 years, TXG annual cash & cash equivalents has fallen by -$243.38 million (-41.43%).
- TXG annual cash & cash equivalents is now -48.15% below its all-time high of $663.60 million, reached on December 31, 2020.
Performance
TXG Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$482.08M+$34.82M(+7.79%)Summary
- As of today, TXG quarterly cash & cash equivalents is $482.08 million, with the most recent change of +$34.82 million (+7.79%) on September 30, 2025.
- Over the past year, TXG quarterly cash & cash equivalents has increased by +$83.92 million (+21.08%).
- TXG quarterly cash & cash equivalents is now -41.79% below its all-time high of $828.22 million, reached on September 30, 2020.
Performance
TXG Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TXG Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | -4.2% | +21.1% |
| 3Y3 Years | -41.4% | +6.5% |
| 5Y5 Years | -18.9% | -41.8% |
TXG Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -41.4% | +56.6% | at high | +34.9% |
| 5Y | 5-Year | -48.1% | +56.6% | -41.8% | +34.9% |
| All-Time | All-Time | -48.1% | +619.0% | -41.8% | +930.8% |
TXG Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $482.08M(+7.8%) |
| Jun 2025 | - | $447.26M(+4.8%) |
| Mar 2025 | - | $426.90M(+8.5%) |
| Dec 2024 | $344.07M(-4.2%) | $393.40M(-1.2%) |
| Sep 2024 | - | $398.16M(+4.8%) |
| Jun 2024 | - | $380.09M(+2.2%) |
| Mar 2024 | - | $371.81M(-4.3%) |
| Dec 2023 | $359.28M(+63.5%) | $388.69M(+8.8%) |
| Sep 2023 | - | $357.41M(-9.0%) |
| Jun 2023 | - | $392.88M(-6.6%) |
| Mar 2023 | - | $420.79M(-2.7%) |
| Dec 2022 | $219.75M(-62.6%) | $432.62M(-4.5%) |
| Sep 2022 | - | $452.89M(-9.5%) |
| Jun 2022 | - | $500.24M(-7.3%) |
| Mar 2022 | - | $539.35M(-8.3%) |
| Dec 2021 | $587.45M(-11.5%) | $588.48M(-2.0%) |
| Sep 2021 | - | $600.47M(-6.2%) |
| Jun 2021 | - | $640.11M(+0.7%) |
| Mar 2021 | - | $635.36M(-6.6%) |
| Dec 2020 | $663.60M | $680.17M(-17.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $828.22M(+108.3%) |
| Jun 2020 | - | $397.69M(+6.8%) |
| Mar 2020 | - | $372.43M(+564.6%) |
| Dec 2019 | $424.17M(+551.8%) | - |
| Jun 2019 | - | $56.03M(-13.9%) |
| Dec 2018 | $65.08M(+36.0%) | $65.08M(+36.0%) |
| Dec 2017 | $47.86M | - |
| Dec 2017 | - | $47.86M(-91.2%) |
| Sep 2017 | - | $546.40M(+862.7%) |
| Jun 2017 | - | $56.76M(-2.5%) |
| Mar 2017 | - | $58.23M(+0.9%) |
| Dec 2016 | - | $57.70M(-15.2%) |
| Sep 2016 | - | $68.07M(-36.0%) |
| Jun 2016 | - | $106.35M(+11.3%) |
| Mar 2016 | - | $95.58M(+104.4%) |
| Dec 2015 | - | $46.77M(-84.2%) |
| Sep 2015 | - | $296.37M(+21.0%) |
| Jun 2015 | - | $244.93M(-2.1%) |
| Mar 2015 | - | $250.13M(-33.0%) |
| Dec 2014 | - | $373.14M |
FAQ
- What is 10x Genomics, Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for 10x Genomics, Inc.?
- What is 10x Genomics, Inc. annual cash & cash equivalents year-on-year change?
- What is 10x Genomics, Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for 10x Genomics, Inc.?
- What is 10x Genomics, Inc. quarterly cash & cash equivalents year-on-year change?
What is 10x Genomics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of TXG is $344.07M
What is the all-time high annual cash & cash equivalents for 10x Genomics, Inc.?
10x Genomics, Inc. all-time high annual cash & cash equivalents is $663.60M
What is 10x Genomics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, TXG annual cash & cash equivalents has changed by -$15.22M (-4.24%)
What is 10x Genomics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of TXG is $482.08M
What is the all-time high quarterly cash & cash equivalents for 10x Genomics, Inc.?
10x Genomics, Inc. all-time high quarterly cash & cash equivalents is $828.22M
What is 10x Genomics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, TXG quarterly cash & cash equivalents has changed by +$83.92M (+21.08%)